ArticleEuropean journal of epidemiology2021
Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel.
Article in European journal of epidemiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Differential COVID-19 infection rates in children, adults, and elderly: Systematic review and meta-analysis of 38 pre-vaccination national seroprevalence studies.Journal of global health · 2023Pooled it
- Age-stratified infection fatality rate of COVID-19 in the non-elderly population.Environmental research · 2023Pooled it
- Seroprevalence of SARS-CoV-2 and risk factors for infection among children in Uganda: a serial cross-sectional study.medRxiv : the preprint server for health sciences · 2024Article
- Seroprevalence of SARS-CoV-2 and risk factors for infection among children in Uganda: A serial cross-sectional study.PloS one · 2024Article
- Study of seroprevalence of SARS-CoV-2 in Kazakhstan.Epidemiology and infection · 2023Article
- Educational intervention for the main caregiver of primiparous women to promote breastfeeding and the association between prolactin and nutritional parameters.Journal of global health · 2023Observational
- National and regional prevalence of SARS-CoV-2 antibodies in primary and secondary school children in England: the School Infection Survey, a national open cohort study, November 2021SARS-CoV-2 antibody prevalence in school children.The Journal of infection · 2023Article
- Trajectories of Seroprevalence and Neutralizing Activity of Antibodies against SARS-CoV-2 in Southern Switzerland between July 2020 and July 2021: An Ongoing, Prospective Population-Based Cohort Study.International journal of environmental research and public health · 2023Article
- Long-Term Antibody Response to SARS-CoV-2 in Children.Journal of clinical immunology · 2023Article
- Structural factors associated with SARS-CoV-2 infection risk in an urban slum setting in Salvador, Brazil: A cross-sectional survey.PLoS medicine · 2022Article
- COVID-19 in Tunisia (North Africa): Seroprevalence of SARS-CoV-2 in the General Population of the Capital City Tunis.Diagnostics (Basel, Switzerland) · 2022Article
- Sero-prevalence of SARS-CoV-2 in certain cities of Kazakhstan.Health science reports · 2022Article
- COVID-19 prevalence and mortality in longer-term care facilities.European journal of epidemiology · 2022Review
- Infection fatality rate of COVID-19 in community-dwelling elderly populations.European journal of epidemiology · 2022Article
- Structural factors contributing to SARS-CoV-2 infection risk in the urban slum setting.medRxiv : the preprint server for health sciences · 2022Article
- Nationally representative SARS-CoV-2 antibody prevalence estimates after the first epidemic wave in Mexico.Nature communications · 2022Article
- A global assessment of the impact of school closure in reducing COVID-19 spread.Philosophical transactions. Series A, Mathematical, physical, and engineering sciences · 2022Article
- Modelling COVID-19 vaccine breakthrough infections in highly vaccinated Israel-The effects of waning immunity and third vaccination dose.PLOS global public health · 2022Article
- Seroprevalence of anti-SARS-CoV-2 antibodies in Thai adults during the first three epidemic waves.PloS one · 2022Article
- Spatio-temporal spread of COVID-19: Comparison of the inhomogeneous SEPIR model and data from South Carolina.PloS one · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The first local spread of COVID-19 in Israel was detected in March 2020. Due to the diversity in clinical presentations of COVID-19, diagnosis by RT-PCR alone might miss patients with mild or no symptoms. Serology testing may better evaluate the actual magnitude of the spread of infection in the population. This is the first nationwide seroprevalence study conducted in Israel. It is one of the most widespread to be conducted thus far, and the largest per-country population size. The survey was conducted between June 28 and September 14, 2020 and included 54,357 patients who arrived at the Health Maintenance Organizations to undergo a blood test for any reason. A patient was considered seropositive after two consecutive positive results with two different kits (Abbott and DiaSorin).The overall seroprevalence was 3.8% (95%CI 3.7-4.0), males higher than females [4.9% (95%CI 4.6-5.2) vs. 3.1% (95%CI 2.9-3.3) respectively]. Adolescents had the highest prevalence [7.8% (95%CI 7.0-8.6)] compared to other age groups. Participants who had undergone RT-PCR testing had a tenfold higher risk to be seropositive. The prevalence-to-incidence ratio was 4.5-15.7. Serology testing is an important complimentary tool for assessing the actual magnitude of infection and thus essential for implementing policy measures to control the pandemic. A positive serology test result was recently accepted in Israel as being sufficient to define recovery, with possible far-reaching consequences, such as the deploying of employees to ensure the maintenance of a functional economy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.